Hong Kong Positions Itself as Global Biotech Bridge

Financial Secretary Paul Chan announced that Hong Kong is ready to serve as the “partner of choice” linking global capital with Chinese biotech innovation. In a speech at BIOHK2026, Chan highlighted that last year’s global biotech fundraising topped US$70 billion, while deal value reached an all‑time high of US$300 billion, driven by ageing populations, rising healthcare needs and AI‑powered drug discovery. Hong Kong ranks as the world’s second‑largest biotech fundraising hub, hosting nearly 300 healthcare companies on the Stock Exchange with a combined market cap above US$480 billion. A listing in Hong Kong connects emerging pharmaceutical firms to worldwide investors and grants international investors direct access to Chinese innovation. Chan noted that the Hong Kong Investment Corporation has earmarked 22 percent of its funds for biotech and the Greater Bay Area, and that five of the world’s top ten pharma firms have chosen Hong Kong for regional R&D. The announcement signals Hong Kong’s intent to boost biotech listings and attract foreign capital, potentially raising the number of biotech IPOs and deepening access to Chinese innovation for global investors.